These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 9718866)

  • 1. rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical approach.
    Rodríguez JN; Martino ML; Diéguez JC; Prados D
    Haematologica; 1998 Jul; 83(7):616-21. PubMed ID: 9718866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature.
    Cervantes F; Alvarez-Larrán A; Hernández-Boluda JC; Sureda A; Torrebadell M; Montserrat E
    Br J Haematol; 2004 Nov; 127(4):399-403. PubMed ID: 15521916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Human recombinant erythropoietin in the treatment of myelodysplastic syndromes anemia. Meta-analytic study].
    Rodríguez JN; Diéguez JC; Muñiz R; Martino ML; Fernández-Jurado A; Amian A; Cañavate M; Prados D
    Sangre (Barc); 1994 Dec; 39(6):435-9. PubMed ID: 7855695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Danazol treatment of idiopathic myelofibrosis with severe anemia.
    Cervantes F; Hernández-Boluda JC; Alvarez A; Nadal E; Montserrat E
    Haematologica; 2000 Jun; 85(6):595-9. PubMed ID: 10870115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
    Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
    Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin.
    Hasselbalch HC; Clausen NT; Jensen BA
    Am J Hematol; 2002 Jun; 70(2):92-9. PubMed ID: 12111781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin treatment of idiopathic myelofibrosis.
    Aloe Spiriti M; Latagliata R; Avvisati G; Battistel V; Montefusco E; Spadea A; Petti MC
    Haematologica; 1993; 78(6):371-3. PubMed ID: 8175031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclosporin-A in severe refractory anemia of myelofibrosis with myeloid metaplasia: a preliminary report.
    Centenara E; Guarnone R; Ippoliti G; Barosi G
    Haematologica; 1998 Jul; 83(7):622-6. PubMed ID: 9718867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis.
    Tsiara SN; Chaidos A; Bourantas LK; Kapsali HD; Bourantas KL
    Acta Haematol; 2007; 117(3):156-61. PubMed ID: 17159338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
    Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
    Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial.
    Silver M; Corwin MJ; Bazan A; Gettinger A; Enny C; Corwin HL
    Crit Care Med; 2006 Sep; 34(9):2310-6. PubMed ID: 16878035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human erythropoietin therapy after allogeneic hematopoietic cell transplantation with a nonmyeloablative conditioning regimen: low donor chimerism predicts for poor response.
    Vanstraelen G; Baron F; Willems E; Bonnet C; Hafraoui K; Frère P; Fillet G; Beguin Y
    Exp Hematol; 2006 Jul; 34(7):841-50. PubMed ID: 16797411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of response to treatment with recombinant human erythropoietin in anaemia associated with cancer.
    Beguin Y
    Med Oncol; 1998 Aug; 15 Suppl 1():S38-46. PubMed ID: 9785336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy.
    Cazzola M; Ponchio L; Pedrotti C; Farina G; Cerani P; Lucotti C; Novella A; Rovati A; Bergamaschi G; Beguin Y
    Haematologica; 1996; 81(5):434-41. PubMed ID: 8952157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2004 Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients.
    Gejyo F; Saito A; Akizawa T; Akiba T; Sakai T; Suzuki M; Nishi S; Tsubakihara Y; Hirakata H; Bessho M;
    Ther Apher Dial; 2004 Dec; 8(6):443-59. PubMed ID: 15663544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human erythropoietin in the treatment of myelodysplastic syndromes. An interim report.
    Aloe Spiriti MA; Petti MC; Latagliata R; Avvisati G; De Gregoris C; Proia S; Fazi P; Jaalouk G; Mancini M; Spadea A
    Haematologica; 1993; 78(2):123-6. PubMed ID: 8349188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Predictive response variables to recombinant human erythropoietin treatment in patients with anemia and cancer].
    Lastiri JM; Specterman SR; Rendo P; Pallotta MG; Varela MS; Goldstein S
    Medicina (B Aires); 2002; 62(1):41-7. PubMed ID: 11965849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
    Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum erythropoietin and creatinine concentrations as predictive factors for response to recombinant human erythropoietin treatment in anaemic tumour patients on chemotherapy.
    Fjornes T; Wiedemann GJ; Sack K; Jelkmann W
    Oncol Rep; 1998; 5(1):81-6. PubMed ID: 9458299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.